A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy

The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer patients who have failed prior Gemcitabine-based systemic therapy.

Start Date01 Oct 2026

Sponsor / Collaborator

Suzhou Medilink Therapeutics Ltd.

NCT07739758

/ RecruitingPhase 3

A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with serplulimab as first-line treatment in patients with extensive-stage small cell lung cancer.

Start Date18 Aug 2026

Sponsor / Collaborator

Suzhou Medilink Therapeutics Ltd.

[+1]

NCT07407933

/ RecruitingPhase 1/2

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.

Start Date31 Mar 2026

Sponsor / Collaborator

Suzhou Medilink Therapeutics Ltd.

[+2]

100 Clinical Results associated with Tambotatug Pelitecan

100 Translational Medicine associated with Tambotatug Pelitecan

100 Patents (Medical) associated with Tambotatug Pelitecan

Literatures (Medical) associated with Tambotatug Pelitecan

03 Apr 2026·Therapeutic Delivery

Industry update January 2026

Review

Author: Rosenmayr-Templeton, Louise

This update is a snap-shot of industry events which occurred during January 2026. The year started well for Eli Lilly with the purchase of Ventyx Biosciences and the signing of two separate collaboration and licensing agreements with Nimbus Therapeutics and Repertoire Immune Medicines for the development of obesity and autoimmune diseases therapies, respectively. AstraZeneca was also in the business of strengthening its obesity and metabolic disease pipeline through an 8-program agreement with CSPC Pharmaceuticals. The deal is potentially worth up to a staggering US$ 18.5 billion in upfront and milestone payments to the Chinese company if all development, regulatory, commercialization and sales goals are met. The agreement also gives AstraZeneca access to CSPC's LiquidGel once monthly dosing technology for its own in-house programs. Elsewhere, Amgen bought out Dark Blue Therapeutics, whose lead MLLT1/3 degrader, DBT 3757, has shown promise in acute leukemia preclinical models; while Roche paired up again with MediLink Therapeutics, this time to advance the antibody-drug conjugate, YL201, which is currently in Phase 3 studies in China for small cell lung cancer and nasopharyngeal carcinoma.

01 Nov 2025·BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application

Review

Author: Wang, Haoyu ; Zhang, Chenyue ; Wang, Haiyong

Antibody-drug conjugates (ADCs), one of the emerging developing classes of antitumor drugs, have transformed the therapeutic paradigm in oncology. It stands out due to its properties of boasting the strength of both chemotherapy and targeted therapy. In small cell lung cancer (SCLC), ADC has also demonstrated its potential and appealing effect. Clinical trials of ADCs in SCLC are currently in full swing. While ADC has brought some encouraging results so far, several obstacles have been encountered, such as drug resistance, drug toxicities and the difficulty in the selection of patients benefiting from ADCs. Thus, a deepened and comprehensive understanding of the fundamental researches, as well as summarization of ADC development in SCLC might offer us some enlightenment and solutions to these tricky issues. Therefore, in the present review, we elaborate on the structure and mechanism of ADC, clinical trials conducted in SCLC. Additionally, we also outline the obstacles and propose future directions of ADC in SCLC, highlighting its in-depth research and prospective application in SCLC.

01 Jun 2025·NATURE MEDICINE

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Article

Author: Xue, Tongtong ; Liu, Zhihua ; Hong, Shaodong ; Lian, Wei ; Zhao, Shen ; Zhang, Xian ; Zheng, Yulong ; Zhang, Li ; Li, Bihui ; Li, Mingjun ; Li, Jingao ; Zhao, Yanqiu ; Fan, Yun ; Huang, Yan ; Liu, Jian ; Wu, Lin ; Qu, Song ; Rosen, Seth ; Yang, Shujun ; Zhuang, Wu ; Meng, Xiangjiao ; Cai, Jiaqiang ; Fang, Wenfeng ; Sommerhalder, David ; Chin, Steve ; Ma, Yuxiang ; Lv, Dongqing ; Zhao, Yuanyuan ; Zhang, Peng ; Luo, Suxia ; Yang, Yunpeng ; Fu, Siqing ; Yang, Kunyu ; Ji, Yinghua ; Zhang, Yang ; Xue, Jinhui ; Zhao, Hongyun

Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker. Here we report the findings from a large-scale, global, multicenter, phase 1 trial evaluating the safety, pharmacokinetics and preliminary efficacy of YL201 in patients with advanced solid tumors refractory to standard therapies. The trial included a dose-escalation part (phase 1) and a dose-expansion part (phase 1b). A total of 312 patients were enrolled across multiple tumor types, including extensive-stage small cell lung cancer (ES-SCLC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer, esophageal squamous cell carcinoma and other solid tumors. The maximum tolerated dose was determined to be 2.8 mg kg^-1, and the recommended expansion dose was selected as 2.0 mg kg^-1 and 2.4 mg kg^-1 every 3 weeks. The most common grade 3 or higher treatment-related adverse events included neutropenia (31.7%), leukopenia (29.5%) and anemia (25.0%). Only 4 cases of interstitial lung disease (1.3%) and 1 case of infusion reactions (0.3%) were observed. Encouraging anti-tumor activity was observed, particularly in patients with ES-SCLC (objective response rate (ORR), 63.9%), NPC (ORR, 48.6%), lung adenocarcinoma (ORR, 28.6%) and lymphoepithelioma-like carcinoma (ORR, 54.2%). No significant correlation between B7H3 membrane expression and the ORR was found. YL201 demonstrated an acceptable safety profile and a promising efficacy in heavily pretreated patients with advanced solid tumors, particularly in those with ES-SCLC, NPC or lymphoepithelioma-like carcinoma. Phase 3 clinical trials for patients with SCLC and NPC have already been initiated. ClinicalTrials.gov identifiers: NCT05434234 and NCT06057922 .

News (Medical) associated with Tambotatug Pelitecan

28 Sep 2026

·www.biopharmadive.com

Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

Dive Brief:Merck & Co. and Daiichi Sankyo have withdrawn a U.S. approval applicationfor an experimental lung cancer drug in a setback that erases an edge the companies had on multiple rivals.Merck and Daiichi had sought an accelerated approval for the drug, ifinatamab deruxtecan, or I-DXd, in extensive-stage small-cell lung cancer based on response rates to treatmentin Phase 2 testing. A decision was expected by Oct. 10. But the Food and Drug Administration indicated those findings arent sufficient to warrant such a clearance in that indication, leading the companies to pull their request.I-DXd is currently being evaluated against chemotherapy in a late-stage trial in patients with relapsed disease. Results from that study, if positive, could support a traditional approval request. But Merck and Daiichi have reported a setback in that trial, too, as recruitment was temporarily halted late last yearwhen a higher than anticipated number of deaths from a serious lung condition was observed among treatment recipients.Dive Insight:Merck is bracing for the day next decade when Keytruda, its top moneymaker, loses patent protection. The company is leaning on many different emerging therapies to offset the coming losses, and antibody-drug conjugates a popular kind of precision cancer medicine are one key area of focus.Over the last several years, the company has struck deals with Daiichi Sankyo and Kelun-Biotech to obtain multiple ADCs that are now in advanced testing. One called sac-TMT, for instance, is now seen by Merck executives as a future cornerstone therapy and is involved in 17 global trials. I-DXd is in the mix, too, though Wall Streets expectations have cooled as competing programs have progressed.I-DXd targets a protein called B7-H3 thats overexpressed in small-cell lung cancer, a particularly aggressive lung tumor with a poor prognosis. At a recent medical meeting, this kind of approach was prominently featured as potentially changing care in patients whose disease is extensive, or has spread to both lungs or other parts of the body. In Phase 3 studies run in China, two prospects recently licensed to Roche and GSK, respectively, showed the potential to substantially outperform chemotherapy without, so far, the level of interstitial lung disease, a potentially deadly form of lung inflammation, observed in testing of I-DXd.GSK has already begun global testing of its B7-H3 drug, riz-rez. Roche could soon follow with its prospect, tam-peli. The progress of both of those medicines, combined with I-DXds previous setbacks, have left investors ascribing very little value to Mercks drug, wrote RBC Capital Markets analyst Trung Huynh.We came away from [those recent presentations] believing that both riz-rez and tam-peli had a better safety profile than I-DXd, Huynh wrote.An accelerated approval could have given Merck an edge on its rivals. But the FDAs decision stance isnt entirely unsurprising given the limited results underlying the submission and the increased scrutiny the agency has been applying in such cases, Huynh wrote. With the application now pulled, GSK has a roughly two month lead on Merck in SCLC, he added.Merck and Daiichis decision also suggests the bar for demonstrating a meaningful advantage in SCLC may have risen following the clearance of Amgens Imdelltra,wrote Cantor Fitzgeralds Li Watsek.Zai Lab and Ideaya Biosciences, the developers of two different kinds of ADCs for SCLC in advanced testing, could benefit, Watsek added. Zai Labs zoci is in pivotal testing and could become the first ADC approved for the condition, while Ideayas may begin a late-stage trial by the end of 2026.Outside of lung cancer, Merck and Daiichi are also testing I-DXd in two other Phase 3 trials in prostate cancer and esophageal squamous cell carcinoma. '

Phase 3ADCAccelerated ApprovalClinical ResultDrug Approval

28 Sep 2026

·www.biospace.com

Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

iStock, wildpixel Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets. Merck and Daiichi Sankyo have voluntarily withdrawn an application seeking accelerated approval for the antibody-drug conjugate ifinatamab deruxtecan after the FDA found that the companies’ data package did not meet the criteria. The pharma partners were proposing to use the ADC, also called I-DXd, for patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease had progressed on or after platinum-based chemotherapy. In regulatory discussions, the FDA indicated that the data supporting I-DXd’s submission “do not satisfy requirements needed to support an accelerated approval for the proposed indication,” according to a Friday news release . “This is an incremental negative setback” for Merck, analysts at RBC Capital Markets told investors in a Sept. 27 note, contending that much of investors’ focus remains on the Kelun-Biotech-partnered TROP2-targeting ADC sacituzumab tirumotecan , being tested for non-small cell lung cancer. Merck and Daiichi Sankyo continue to study I-DXd in a Phase 3 trial for ES-SCLC, which could be used for a future regulatory filing, Daiichi said in a statement. Enrollment is nearing completion for the study, according to Daiichi’s Abderrahmane Laadem, head of therapeutic area oncology development. BioSpace has reached out for more details. “While we are disappointed that the current dataset are not supportive of an approval at this time, we are continuing to evaluate the role of ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer and other types of difficult-to-treat cancer,” Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, said in a prepared statement. I-DXd is also being tested in two other Phase 3 trials: IDeate-Prostate01 for metastatic castration-resistant prostate cancer and IDeate-Esophageal01 for advanced esophageal squamous cell carcinoma. While not great news for Merck, I-DXd’s setback “is a net positive” for SCLC competitors GSK and Roche, RBC noted. GSK and Hansoh Pharma are developing the B7-H3 ADC risvutatug rezetecan (ris-rez), which during the recent World Conference on Lung Cancer (WCLC) achieved median overall survival (OS) of 18.5 months, versus 10.3 months in standard-of-care controls, according to a late-stage study conducted in China. Roche, meanwhile, is working with China’s MediLike Therapeutics on the ADC tambotatug pelitecan (tam-peli), which also demonstrated promising results at the WCLC, with a median OS of 13.3 months versus 9.4 months in comparators on standard of care in a Phase 3 study in China. GSK expects to submit regulatory filings for ris-rez in 2028 , while Roche plans to initiate global late-stage studies “ quickly ,” CMO Levi Garraway said earlier this month. Lung cancer Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new findings for their closely watched programs, highlighting overall survival benefits in various types of lung cancer. September 14, 2026 · 4 min read · Gabrielle Masson Read more Merck and Daiichi Sankyo supported their accelerated approval application for I-DXd with data from the Phase 2 IDeate-Lung01 study, which last September demonstrated a 48.2% confirmed objective response rate in patients with ES-SCLC. In December, however, the FDA placed I-DXd’s late-stage development program in this indication on clinical hold after detecting a “higher than anticipated incidence” of interstitial lung disease leading to death in the Phase 3 IDeate-Lung02 trial. The regulator lifted the pause in January. In more positive news, Merck on Friday reported the expanded approval of the HIF-2α therapy Welireg for advanced renal cell carcinoma with a clear cell component, indicated for patients who had undergone prior treatment with a PD-L1 blocker. ADCs Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan. January 13, 2026 · 3 min read · Tristan Manalac Read more

Phase 3Clinical ResultADCAccelerated ApprovalDrug Approval

18 Sep 2026

·www.fiercepharma.com

Fierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEO

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports. Akeso and Summit Therapeutics' ivonescimab, B7-H3 antibody-drug conjugates and a surprise negative overall survival trend from Enhertu headlined WCLC26. Plus more. 1. US weighs allowing most pharma licensing deals with China, sources say (Reuters) The U.S. Treasury Department is working on rules that would allow most licensing deals for Chinese drugs, Reuters reports, citing three people who have been briefed on the process. The rules are likely to allow U.S. companies to continue buying new drug candidates from Chinese companies as long as they are not related to pathogens or technologies that could be weaponized, the sources reportedly told Reuters. Lawmakers hawkish on China have asked the Treasury to crack down on biopharma transactions with China under the COINS Act. 2. Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients Ivonescimab’s detailed head-to-head overall survival win against Keytruda revealed a 27% benefit in first-line, PD-L1-positive non-small cell lung cancer in the China phase 3 Harmoni-2 trial. The Akeso-Summit PD-1xVEGF bispecific prolonged median OS by 8.2 months to 30.8 months. The drug showed especially strong results in PD-L1-high patients, lowering the risk of death by 42% versus Merck’s PD-1 inhibitor. 3. GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival The B7-H3 antibody-drug conjugate race is heating up among Chinese assets licensed to Big Pharma. GSK’s Hansoh-partnered ris-rez achieved a median OS of 18.5 months in a China phase 3 small cell lung cancer trial in previously treated patients. Roche’s partner MediLink reported a median OS of 12 months for their candidate, tam-peli, in a separate second-line SCLC trial in China. Cross-trial comparisons should be viewed with caution. 4. Increased deaths shadow AstraZeneca, Daiichi’s Enhertu first-line lung cancer data In a rare setback for AstraZeneca and Daiichi Sankyo’s Enhertu, the star HER2 ADC showed a negative OS trend against Keytruda plus chemotherapy in first-line, HER2-mutant NSCLC. While the phase 3 Destiny-Lung04 trial met its progression-free survival endpoint, an interim OS analysis found that patients in the Enhertu arm lived a median 29.3 months, versus 33.1 months in the control arm. 5. Legend Biotech names Novartis veteran Ingrid Zhang as new CEO Legend Biotech has named Novartis’ former China head, Ingrid Zhang, as its new CEO. Zhang, who most recently served as chief commercial officer for Novartis’ ex-U.S. business, succeeded interim chief Alan Bash, who has resumed his role as president of Carvykti. In a LinkedIn post shortly before the announcement, Zhang said patient access has “shaped how I’ve led.” 6. GSK doubles down on Chimagen with $750M multiple myeloma wager GSK licensed a trispecific T-cell engager from China’s Chimagen Biosciences for up to $750 million. The disease is multiple myeloma, but the three targets were not disclosed. The program is expected to enter clinical testing in 2027. 7. Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results 8. BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout 9. Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer 10. BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms 11. SK pens $315M pact with fellow South Korean company for Parkinson’s prospect 12. AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

Phase 3Clinical ResultExecutive ChangeADC

100 Deals associated with Tambotatug Pelitecan

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Lung Small Cell Carcinoma	NDA/BLA	China	Shanghai Yilian Biomedical Co., Ltd.	02 Sep 2026
Nasopharyngeal Carcinoma	NDA/BLA	China	Asymchem Laboratories (Tianjin) Co., Ltd.	18 Jul 2026
Nasopharyngeal Carcinoma	NDA/BLA	China	Shanghai Yilian Biomedical Co., Ltd.	18 Jul 2026
Metastatic Pancreatic Cancer	Phase 3	China	Suzhou Medilink Therapeutics Ltd.	22 Sep 2026
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	China	Suzhou Medilink Therapeutics Ltd.	22 Sep 2026
Extensive stage Small Cell Lung Cancer	Phase 3	China	Suzhou Medilink Therapeutics Ltd.	12 Aug 2026
Advanced Esophageal Squamous Cell Carcinoma	Phase 3	China	Suzhou Medilink Therapeutics Ltd.	24 Mar 2026
Small cell lung cancer limited stage	Phase 3	China	Suzhou Medilink Therapeutics Ltd.	17 Dec 2024
Lung Cancer	Phase 2	Belgium	Suzhou Medilink Therapeutics Ltd.	31 Mar 2026
Lung Cancer	Phase 2	Hungary	Suzhou Medilink Therapeutics Ltd.	31 Mar 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06394414 (WCLC2026 \| Corporate Publications) Manual	Phase 1	Extensive stage Small Cell Lung Cancer \| Advanced Lung Non-Small Cell Carcinoma First line CD276 \| PD-L1	85	YL201 2.0 mg/kgYL201 2.0 mg/kg plus serplulimab 4.5 mg/kg IV every 3 weeks	nwflayyhvb(xzsyhbubrh) = mlngpksffm gkdwiehmjc (kjrkhkulhq ) View more	Positive	12 Sep 2026
				YL201 2.0 mg/kgYL201 2.0 mg/kg plus serplulimab 4.5 mg/kg IV every 3 weeks (Extensive-stage small cell lung cancer)	dulllhguph(ykqtsegdyo) = kgoruixrtq tkeqdrizzl (aklxwxxznr, 70.8 - 94.4) View more
NCT06241846 (ASCO2026)	Phase 2	Metastatic castration-resistant prostate cancer	82	YL201 2.0 mg/kg	muzdltritn(thdwsmafkl) = ktwbpqjmmn ixqlczwrdh (egmzrdoxau, 18.5 - 42.6) View more	Positive	29 May 2026
				YL201 2.4 mg/kg	muzdltritn(thdwsmafkl) = xmeoastdii ixqlczwrdh (egmzrdoxau ) View more
NCT06057922 (ASCO2026)	Phase 1/2	Chondrosarcoma \| Refractory Ewing Sarcoma	32	YL201 (Ewing sarcoma)	epwhaidelz(eqvgydidyf) = wrwevjklby byqowyfdbt (aqpvziypbf, 27.2 - 72.8) View more	Positive	29 May 2026
				YL201 (chondrosarcoma)	epwhaidelz(eqvgydidyf) = bsorbiqtle byqowyfdbt (aqpvziypbf, 0.3 - 44.5) View more
NCT05434234 \| NCT06057922 (Pubmed \| Nat Med \| NEWS 1 \| NEWS 2) Manual	Phase 1	Extensive stage Small Cell Lung Cancer \| Advanced Malignant Solid Neoplasm \| Nasopharyngeal Carcinoma ... View more	312	YL201	ypnqpkwlnt(gmmnmwqnjd) = nlscxjhpyb lzagsougfq (vrmxmzscil ) View more	Positive	01 Jun 2025
				YL201 (Extensive-stage small cell lung cance)	gtyxnmnlwg(sxnnvxjxxm) = mklfrnoakd utyoipnqbm (hlxvwhlicr ) View more
NCT05434234 \| NCT06057922 (ESMO_ELCC2025) Manual	Phase 1	Extensive stage Small Cell Lung Cancer \| Non-Small Cell Lung Cancer	29	YL201 (SCLC + brain target lesion)	vrsgixabtq(fqdbmxgkvb) = hfrutualkh lvdjbribco (wxwhfojlsi, 69.2–100) View more	Positive	26 Mar 2025
				YL201 (WT NSCLC + brain target lesion)	vrsgixabtq(fqdbmxgkvb) = obprtnklrx lvdjbribco (wxwhfojlsi, 29.2–100) View more
NCT06612151 (NEWS) Manual	Phase 3	Small Cell Lung Cancer	438	YL201	bkoiafqwyw(kiyyrlyxiv) = pnirfzazvo gkhvazqfqc (fdnedrjlao ) View more	Positive	26 Sep 2024
				YL201 (SCLC)	bkoiafqwyw(kiyyrlyxiv) = gjrroebnrn gkhvazqfqc (fdnedrjlao ) View more
NCT05434234 \| NCT06057922 (ESMO2024) Manual	Phase 1	Advanced Malignant Solid Neoplasm \| Small Cell Lung Cancer \| Nasopharyngeal Carcinoma ... View more	276	YL201	fcftozlqms(dhbfbcscpn) = leukopenia (52.9%; grade [G]≥3: 22.5%), anemia (51.1%; G≥3: 14.9%) and neutropenia (48.9%; G≥3: 23.9%) dtwsrerdpf (rwfwizmtau ) View more	Positive	13 Sep 2024
				YL201 2.0 mg/kg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis